National Institutes of Health: Influenza, Human trials

The registry lists 190 Influenza, Human studies with National Institutes of Health as lead sponsor. 12 are open to participants now and 54 have results posted.

Phase 1 96Phase 2 70Phase 3 5Phase 4 11No phase 27(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine CandidatesNot yet recruitingNCT07703514Phase 1
• Rechallenge With a Low Pathogenicity Avian H10N7 Influenza Virus in Healthy Human Volunteers Previously Challenged With H10N7 InfluenzaEnrolling by invitationNCT07215871Phase 1
• BPL-1357 Against H1N1 Influenza Virus ChallengeRecruitingNCT07215858Phase 2
• First-in-Human Study of VNT-101: Safety, Tolerability, and PharmacokineticsRecruitingNCT07169318Phase 1
• Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)RecruitingNCT07149428
• pH1N1 Blinded Challenge StudyRecruitingNCT07110532Phase 1
• Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy AdultsRecruitingNCT06863142Phase 1
• High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) RecipientsRecruitingNCT05947071Phase 2
• Respiratory Virus Sampling and RepositoryRecruitingNCT05266222
• Observational Digital Biomarker Discovery in Respiratory Virus Challenge StudiesRecruitingNCT04772170
• Long-term Observation of Hemagglutinin and Neuraminidase Inhibition Antibody Titers After Influenza ChallengeEnrolling by invitationNCT02511002
• Screening for LID Clinical Studies Unit Healthy Volunteer ProtocolsRecruitingNCT01386424
• Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza VaccineCompletedNCT05027932Phase 1Results posted
• Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza StrainCompletedNCT04978454Phase 1Results posted
• Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza VaccineTerminatedNCT04960397Phase 1Results posted
• First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy AdultsCompletedNCT04896086Phase 1Results posted
• Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy AdultsCompletedNCT04579250Phase 1Results posted
• H1N1v Virus Challenge Study in Healthy SubjectsCompletedNCT04044352Phase 1Results posted
• Systems Analyses of the Immune Response to the Seasonal Influenza VaccineCompletedNCT04025580Phase 2Results posted
• Flublok or Fluzone With Advax-CpG55.2 or AF03CompletedNCT03945825Phase 1Results posted
• Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve IndividualsCompletedNCT03816878Phase 1Results posted
• Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy AdultsCompletedNCT03814720Phase 1Results posted
• 2017 A/H7N9 IIV RevaccinationCompletedNCT03738241Phase 2Results posted
• Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian InfluenzaCompletedNCT03682120Phase 2Results posted
• Development of Childhood Anti-Influenza ImmunityCompletedNCT03673345Phase 4Results posted
• 2013/2017 H7N9 Prime-Boost IntervalCompletedNCT03589807Phase 2Results posted
• H3N2 M2SR in Pediatric PopulationCompletedNCT03553940Phase 1Results posted
• Age and Response to Flu VaccinesTerminatedNCT03328325Phase 4Results posted
• Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4CompletedNCT03318315Phase 2Results posted
• Sanofi 2017 H7N9 With/Without AS03 in Adults/ElderlyCompletedNCT03312231Phase 2Results posted
• Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy AdultsCompletedNCT03186781Phase 1Results posted
• Two Doses of Multimeric-001 (M-001) Followed by Influenza VaccineCompletedNCT03058692Phase 2Results posted
• H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology AnalysesCompletedNCT02921997Phase 2Results posted
• Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza ACompletedNCT02572817Phase 3Results posted
• Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza VaccinationTerminatedNCT02485639Phase 4Results posted
• Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy VolunteersTerminatedNCT02385123Phase 4Results posted
• Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Volunteer Human Challenge ModelCompletedNCT02371668Phase 2Results posted
• Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With InfluenzaCompletedNCT02287467Phase 3Results posted
• Evaluation of Anti-Hemagglutinin (Anti-HA) Antibodies as Protection From the Flu in Healthy PeopleCompletedNCT01971255Phase 1/2Results posted
• Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)CompletedNCT01910519Phase 2Results posted
• Influenza A 2009 H1N1 Challenge Study in Healthy AdultsCompletedNCT01646138Phase 1/2Results posted
• Evaluating the Use of Oseltamivir for the Treatment of Influenza in AdultsCompletedNCT01314911Not applicableResults posted
• Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for ComplicationsCompletedNCT01227967Phase 2Results posted
• Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding WomenCompletedNCT01181323Phase 2Results posted
• 2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant WomenCompletedNCT01173211Phase 2Results posted
• Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating InfluenzaCompletedNCT01052480Phase 2Results posted
• Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and YouthCompletedNCT00992836Phase 2Results posted
• Novartis H1N1 Vaccine in Pregnant WomenCompletedNCT00992719Phase 2Results posted
• H1N1 Vaccine at Two Dose Levels in HIV Positive AdultsCompletedNCT00992433Phase 2Results posted
• Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant WomenCompletedNCT00992017Phase 2Results posted
• Safety and Efficacy of an H1N1 Influenza Vaccine in People With AsthmaCompletedNCT00978120Phase 2Results posted
• H1N1 Vaccine in Pregnant WomenCompletedNCT00963430Phase 2Results posted
• Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly PopulationsCompletedNCT00963157Phase 2Results posted
• Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose LevelsCompletedNCT00944073Phase 2Results posted
• Sanofi H1N1 + TIV - Adults and ElderlyCompletedNCT00943878Phase 2Results posted
• Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly PopulationsCompletedNCT00943631Phase 2Results posted
• CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly PopulationsCompletedNCT00943488Phase 2Results posted
• Sanofi Pasteur, TIV + H1N1, Pediatric PopulationCompletedNCT00943202Phase 2Results posted
• Influenza Vaccine in Pregnant WomenCompletedNCT00905125Phase 2Results posted
• H5N1 Priming and Boosting StrategiesCompletedNCT00703053Phase 2Results posted
• Higher Dose Intradermal H5 VaccineCompletedNCT00439335Phase 1/2Results posted
• Interferon as a Mucosal Adjuvant for Influenza Vaccine Given IntranasallyCompletedNCT00436046Phase 1Results posted
• Open-Label Study of H5 Vaccine in Participants of Protocol 04-077CompletedNCT00402649Phase 1/2Results posted
• Oseltamivir Treatment for Children Less Than 24 Months of Age With InfluenzaCompletedNCT00391768Phase 1/2Results posted
• Development of Immune Globulin Treatment for Avian FluTerminatedNCT00383071Phase 2Results posted
• High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian InfluenzaCompletedNCT00298233Phase 2Results posted
• A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy AdultsCompletedNCT07019883Phase 1
• Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy AdultsCompletedNCT05968989Phase 1
• A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy AdultsCompletedNCT05945485Phase 1
• A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy AdultsCompletedNCT05755620Phase 1
• Low Pathogenicity Avian H10N7 Influenza Virus in a Healthy Human Challenge ModelCompletedNCT05436444Phase 1
• Natural History of Systemic and Nasal Mucosal Immunity After Influenza Vaccination in a Pediatric PopulationCompletedNCT04963166
• Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After VaccinationCompletedNCT04794829
• Mucosal and Systemic Immunity After Viral Challenge of Healthy Volunteers Vaccinated With Inactivated Influenza Vaccine Via the Intranasal Versus Intramuscular RouteCompletedNCT03845231Phase 2
• A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus VaccineCompletedNCT03581903Phase 1
• H5N1 With or Without Topical Aldara in Healthy AdultsCompletedNCT03472976Phase 1
• H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: ImmunologyCompletedNCT03014310Phase 1
• Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 AdjuvantCompletedNCT02957656Phase 1
• Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like VirusWithdrawnNCT02950688Phase 1
• Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v DiseaseTerminatedNCT02883426Phase 1
• H5N8 Mix and Match With or Without AS03 or MF59 in Healthy AdultsCompletedNCT02624219Phase 1
• Influenza A H3N2 Human Challenge Study in Healthy Adult VolunteersCompletedNCT02594189Phase 1
• H7N9 Boost in Healthy AdultsCompletedNCT02586792Phase 2
• Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years OldCompletedNCT02274545Phase 1
• A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus VaccineCompletedNCT02251288Phase 1
• H7N9 Mix and Match With MF59 in Healthy Elderly PersonsCompletedNCT02213354Phase 2
• H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...CompletedNCT02206464Phase 1
• Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying IntervalsCompletedNCT02151344Phase 1
• Zoonotic Influenza Infections of Swine Origin at Ohio Agricultural FairsCompletedNCT02124096
• Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric PopulationsCompletedNCT02100436Phase 2
• A Phase 1, Open Label, Ascending Dose Cohort Study of the Pharmacokinetics of Anti-Influenza Hyperimmune Intravenous Immunoglobulin in Healthy SubjectsWithdrawnNCT02037282Phase 1
• Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)CompletedNCT02008578Phase 1
• Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy AdultsCompletedNCT01995695Phase 1
• H7N9 Mix and Match With AS03 and MF59 in Healthy AdultsCompletedNCT01942265Phase 2
• H7N9 Mix and Match With MF59 in Healthy AdultsCompletedNCT01938742Phase 2
• Testing the AVI-7100 Flu Drug in Healthy VolunteersCompletedNCT01747148Phase 1
• Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Adult and Elderly PopulationsCompletedNCT01746082Phase 2
• Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 YearsCompletedNCT01676402Phase 1
• Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus VaccinesCompletedNCT01674205Phase 1
• Influenza Antiviral DAS-181-F04 in Healthy AdultsCompletedNCT01651494Phase 1